73
A recent clinical trial shows that tirzepatide leads to greater weight loss than semaglutide in people managing obesity. Participants who took tirzepatide lost an average of 20.2% of their body weight.
The trial specifically looked at how tirzepatide affected weight loss in individuals working to control their obesity. Results revealed that, on average, these individuals reduced their weight by 20.2%.
Advertisements
The study also highlights a clear difference in effectiveness between tirzepatide and semaglutide for weight management within the trial.
Advertisements
